Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...

The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...

The FDA approved a prescription at-home brain neuromodulation therapy as an adjunctive depression treatment for adults, maker ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.

Neurolief announced today that the FDA granted approval for its Proliv Rx at-home neuromodulation therapy for treating ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

At Stanford, a treatment that aims magnetic pulses at the brain is showing results for people with treatment-resistant ...

Financing led by Genesys Capital with participation from Cleveland Clinic and JobsOhio Ventures -- Genesys Capital Managing Partner Jamie Stiff to join Enspire Board of Directors -- Proceeds to ...

Significant improvement in depressive symptoms among patients using Proliv™Rx compared to sham controls. Favorable safety profile with minimal adverse events. High patient adherence and satisfaction ...

Auricular vagal neuromodulation therapy is a non-invasive and non-surgical treatment that could aid cardiovascular disease ...

Data presented at CTAD showed strong separation from placebo and statistical significance in mild-to-moderate patients on key global, cognitive, and behavioral measures including CDR-SB, ADAS- Cog 11 ...

The clinical trial is expected to enroll up to 40 patients in two stages: an initial open-label pilot (10 patients) followed ...